T1	Participants 110 170	patients with hormonally untreated carcinoma of the prostate
T2	Participants 367 455	patients with hormonally untreated carcinoma of the prostate and rising serum PSA levels
T3	Participants 465 480	Eighty patients
T4	Participants 964 1023	Seventy patients completed the study (36 verum; 34 placebo)
T5	Participants 1580 1640	patients with hormonally untreated carcinoma of the prostate
